Canadian guidelines on sexually transmitted infections : treatment of N. gonorrhoeae in response to the discontinuation of spectinomycin : alternative treatment guidance statement.: HP40-1/2017-3E-PDF
“The Public Health Agency of Canada (PHAC) has been informed that manufacturing of spectinomycin has been discontinued. This antimicrobial is therefore no longer available through Health Canada’s Special Access Program (SAP). In the face of increasing antimicrobial resistance in Neisseria gonorrhoeae, the discontinuation of spectinomycin has the potential to limit gonorrhea prevention and control efforts in Canada by further restricting treatment options. This guidance statement for alternative treatments for gonococcal infections was developed in consultation with the CGSTI Expert Working Group based on Canadian epidemiology and a rapid evidence review”--Issue, p. 1.
Permanent link to this Catalogue record:
publications.gc.ca/pub?id=9.836313&sl=0
| Department/Agency | Public Health Agency of Canada. |
|---|---|
| Title | Canadian guidelines on sexually transmitted infections : treatment of N. gonorrhoeae in response to the discontinuation of spectinomycin : alternative treatment guidance statement. |
| Variant title | Treatment of N. gonorrhoeae in response to the discontinuation of spectinomycin : alternative treatment guidance statement |
| Publication type | Monograph |
| Language | [English] |
| Later edition | Canadian guidelines on sexually transmitted infections |
| Format | Electronic |
| Electronic document | |
| Note(s) | Caption title. "May 2017." Includes bibliographical references. |
| Publishing information | [Ottawa] : Public Health Agency of Canada, 2017. |
| Description | 4 p. |
| ISBN | 978-0-660-08486-2 |
| Catalogue number |
|
| Departmental catalogue number | 170052 |
| Subject terms | Sexually transmitted diseases Medicine Guidelines |